Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
The use of plasma cell-free DNA (cfDNA) as a useful biomarker in obstetric clinical practice has been delayed due to the lack of reliable quantification protocols. We developed a protocol to quantify plasma cfDNA using an internal standard strategy to overcome difficulties posed by low levels and high fragmentation of cfDNA. cfDNA was isolated from plasma samples of non-pregnant (NP,
n
= 26) and pregnant (P,
n
= 26) women using a commercial kit and several elution volumes were evaluated. qPCR parameters were optimized for cfDNA quantification, and several quantities of a recombinant standard were evaluated as internal standard. Absolute quantification was performed using a standard curve and the quality of the complete method was evaluated. cfDNA was eluted in a 50-μl volume, actin-β (
ACTB
) was selected as the target gene, and qPCR parameters were optimized. The
ACTB
standard was constructed and 1000 copies were selected as internal standard. The standard curve showed
R
2
= 0.993 and
E
= 109.7%, and the linear dynamic range was defined between 10
2
and 10
6
ACTB
copies/tube. Repeatability and reproducibility in terms of CV were 19% and up to 49.5% for
ACTB
copies per milliliter of plasma, respectively. The range of cfDNA levels was 428–18,851 copies/mL in NP women and 4031–2,019,363 copies/mL in P women, showing significant differences between the groups. We recommend the application of internal standard strategy for a reliable plasma cfDNA quantification. This methodology holds great potential for a future application in the obstetric field.